Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Share voting
View:
Post by dfinal on Mar 27, 2014 10:24am

Share voting

Right now only money being made is animal health . I'm voting to keep it . Managment should sell everything else.

May, 2013, the Company formally commenced the process to divest its Animal Health business and concentrate on becoming a Human Health company. The divestment is proceeding well, with binding offers expected to be tendered before the end of the calendar year.

Revenues for this business unit in Q1, Fiscal 2014 were $7.7 million, as compared to $6.6 million in the same period in Fiscal 2013, a 17% increase. Net income in Q1, Fiscal 2014 was $1.9 million, as compared to net income of $0.08 million in Q1, Fiscal 2013.

The basic and fully diluted earnings per share for this business unit in Q1, Fiscal 2014 is $0.02, as compared to basic and fully diluted earnings per share of $0.00 in the same quarter of Fiscal 2013.

Q1,


Read more at https://www.stockhouse.com/news/press-releases/2013/11/05/bioniche-life-sciences-inc-reports-fiscal-2014-first-quarter-results#b2BGtyeCEwzRyjCs.99
Comment by givmeabrake on Mar 27, 2014 12:25pm
That is a vote for imminent bankruptcy . Drop dead date end of June for loan repayment. Sale is our last life raft and only way out of this mess. Oh unless they announce sale of VCM for 40m$ plus in the next two weeks.  as for dissident wells shares , my guess he sold at 34 in the fall along with Gube. Huge volume at that time . Warning... We MUST vote if we want to survive , in the off ...more  
Comment by Nohandledzep on Mar 27, 2014 2:26pm
I agree...I am voting for plan B. I am not sure what all the whining is about. The share price has only lost 30% of its value since the AH sale was disclosed. More impressively it is only down 25% since the CEO mentioned that Urocidin is a $200 mil asset. As usual, the situation is worse than the most obscene skeptic could dream up. The entire pile of s__t is again valued at less than what was ...more  
Comment by givmeabrake on Mar 27, 2014 4:32pm
Please elaborate .... how is that responsible or sensible? Unless of course you rep Endo, paladin or worse G&W
Comment by Nohandledzep on Mar 27, 2014 4:58pm
I have already Voted GMB...Yes If you are responsible, in the sense that you would like to see Urocidin succeed a real treatment for bladder cancer approved, you vote no, let Bioniche die and Urocidin move on to more capable hands. The same applies to Econiche actually. Unfortunately you were, like me and many here, downright mother fn stupid enough to invest in this apocalyptic POGarbage ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities